Literature DB >> 7793450

Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.

J Benjamin1, J Levine, M Fux, A Aviv, D Levy, R H Belmaker.   

Abstract

OBJECTIVE: Because they found in an earlier study that inositol, an important intracellular second-messenger precursor, was effective against depression in open and double-blind trials, the authors studied its effectiveness against panic disorder.
METHOD: Twenty-one patients with panic disorder with or without agoraphobia completed a double-blind, placebo-controlled, 4-week, random-assignment crossover treatment trial of 12 g/day of inositol.
RESULTS: The frequency and severity of panic attacks and the severity of agoraphobia declined significantly more after inositol than after placebo administration. Side effects were minimal.
CONCLUSIONS: The authors conclude that inositol's efficacy, the absence of significant side effects, and the fact that inositol is a natural component of the human diet make it a potentially attractive therapeutic for panic disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7793450     DOI: 10.1176/ajp.152.7.1084

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  17 in total

1.  Association of Myoinositol Transporters with Schizophrenia and Bipolar Disorder: Evidence from Human and Animal Studies.

Authors:  Marquis P Vawter; Abdul Rezzak Hamzeh; Edgar Muradyan; Olivier Civelli; Geoffrey W Abbott; Amal Alachkar
Journal:  Mol Neuropsychiatry       Date:  2019-08-08

2.  Inositol treatment of autism.

Authors:  J Levine; A Aviram; A Holan; A Ring; Y Barak; R H Belmaker
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Inositol has behavioral effects with adaptation after chronic administration.

Authors:  H Cohen; M Kotler; Z Kaplan; M A Matar; O Kofman; R H Belmaker
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways.

Authors:  Yaoyang Zhang; Michaela D Filiou; Stefan Reckow; Philipp Gormanns; Giuseppina Maccarrone; Melanie S Kessler; Elisabeth Frank; Boris Hambsch; Florian Holsboer; Rainer Landgraf; Christoph W Turck
Journal:  Mol Cell Proteomics       Date:  2011-08-23       Impact factor: 5.911

5.  Epi-inositol and inositol depletion: two new treatment approaches in affective disorder.

Authors:  Y Bersudsky; H Einat; Z Stahl; R H Belmaker
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

6.  Identification of myo-inositol-3-phosphate synthase isoforms: characterization, expression, and putative role of a 16-kDa gamma(c) isoform.

Authors:  Ratnam S Seelan; Jaganathan Lakshmanan; Manuel F Casanova; Ranga N Parthasarathy
Journal:  J Biol Chem       Date:  2009-02-02       Impact factor: 5.157

7.  Behavioral metabolomics analysis identifies novel neurochemical signatures in methamphetamine sensitization.

Authors:  D E Adkins; J L McClay; S A Vunck; A M Batman; R E Vann; S L Clark; R P Souza; J J Crowley; P F Sullivan; E J C G van den Oord; P M Beardsley
Journal:  Genes Brain Behav       Date:  2013-09-30       Impact factor: 3.449

8.  Single photon emission computed tomography (SPECT) in obsessive-compulsive disorder before and after treatment with inositol.

Authors:  P D Carey; J Warwick; B H Harvey; D J Stein; S Seedat
Journal:  Metab Brain Dis       Date:  2004-06       Impact factor: 3.584

9.  The metabolic responses to aerial diffusion of essential oils.

Authors:  Yani Wu; Yinan Zhang; Guoxiang Xie; Aihua Zhao; Xiaolan Pan; Tianlu Chen; Yixue Hu; Yumin Liu; Yu Cheng; Yi Chi; Lei Yao; Wei Jia
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

10.  Assessing the metabolic effects of aromatherapy in human volunteers.

Authors:  Yinan Zhang; Yani Wu; Tianlu Chen; Lei Yao; Jiajian Liu; Xiaolan Pan; Yixue Hu; Aihua Zhao; Guoxiang Xie; Wei Jia
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-02       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.